Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Aldafermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 24 Jun 2023 Results (from studies NCT02443116 and NCT02912260) assessing the concomitant changesof qFibrosis (qF) with qSteatosis (qS) and qBallooning (qB) in zonalregions to evaluate the impact of hepatic fat and LV reduction on fibrosis changes presented at the European Association for the Study of the Liver Congress 2023
- 26 Jun 2022 Results presented at The International Liver Congress 2022
- 26 Jun 2021 Results (n=78) of 24-week assessing cardiovascular risk assessment and key lipoproteins implicated in atherosclerosis presented at The International Liver Congress 2021